The Action and Mechanism of Action of Ligustrazine Promotes on Myocardial Infarction&#894; An Animal Study

Shuai Huang; Xiaoying Song; Xi Zhang

doi:10.23812/j.biol.regul.homeost.agents.20223606.226

Publication Frequency

Quarterly since 2025

Journal Articles

Search scope

Journal Center

Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.

more

Volume Arrangement

2025

Vol 39, No 3 (2025)

Vol 39, No 2 (2025)

Vol 39, No 1 (2025)

Featured Articles

Macrophages in the pathogenesis of psoriasis and anti-psoriatic nanotherapies

Psoriasis is a common, chronic, and inflammatory skin disease. Macrophages account for about 61.3% of the inflammatory cells infiltrating psoriatic lesions. Modulating macrophage polarization, inhibiting their infiltration, and targeting the secretion of inflammatory factors and associated inflammatory pathways by these cells can alleviate psoriasis symptoms and inflammation. Moreover, nanomaterials as novel drug carriers, offer unique advantages such as large surface area, easy modification, high biocompatibility, good biodegradability, enhanced systemic adsorption, etc. Nanomaterials have great potential for efficient drug delivery and release, as well as improving therapeutic efficacy while reducing adverse effects. By systematically addressing the role of macrophages in psoriasis pathogenesis and the potential of nanomaterials in treating psoriasis through modulating macrophages, this review enhances our understanding of the disease mechanism and holds promise for novel therapeutic breakthroughs and advancements in the future treatment of psoriasis.

The Action and Mechanism of Action of Ligustrazine Promotes on Myocardial Infarction; An Animal Study

Shuai Huang, Xiaoying Song, Xi Zhang

Article ID: 7052
Vol 36, Issue 6, 2022

DOI: https://doi.org/10.23812/j.biol.regul.homeost.agents.20223606.226

Received: 8 January 2023; Accepted: 8 January 2023; Available online: 8 January 2023; Issue release: 8 January 2023

Abstract

Purpose: This study investigated the action and mechanism of Ligustrazine (TMP) on myocardial infarction (MI). Methods: A MI model was established, using adult male Sprague-Dawley (SD) rats. Heart function indicators were measured, using echocardiography. Real-time reverse transcription polymerase chain reaction (qRT-PCR) assay was used, to measure the micro ribonucleic acid-181a-5p (miR-181a-5p) expression. The therapeutic effect of (miR-181a-5p) on MI mice was investigated, using western blot. Hematoxylin-eosin (HE) staining was used, to determine the cross-section area (CSA) of myocardial cells. The expression of inflammatory cytokines was determined, using ELISA (enzyme-linked immunosorbent assay) kits. Results: The left ventricular ejection fraction (LVEF), and left ventricular fractional shortening (LVFS) significantly declined while the left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) obviously increased 14 days after MI was established. TMP treatment significantly promoted cardiac function of MI rats. The CSA was significantly elevated in MI rats and TMP treatment significantly abated CSA expression. TMP treatment significantly inhibited the inflammatory cytokines and significantly up-regulated apoptosis-related protein of cardiac tissues in MI rats. In addition, miR-181a-5p significantly increased in MI rats, significantly reversing the therapeutic effect of TMP on MI rats. Signal transducer and activator of transcription 3 (STAT3) was predicted to combine with miR-181a-5p. Conclusions: TMP treatment significantly promoted cardiac function and inhibited the levels of inflammatory cytokines to alleviate MI, by regulating the miR-181a-5p/STAT3 axis.

Keywords

ligustrazine;myocardial infarction;micro ribonucleic acid-181a-5p (miR-181a-5p);signal transducer and activator of transcription 3 (STAT3);cardiac function

References

Supporting Agencies

This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Editor-in-Chief

Dr. Fabio Malavasi

Medical Genetics, University of Torino Medical School, Italy

Co-Editor-in-Chief

Prof. Marcello Iriti

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy

Indexing & Archiving

News & Announcements

2025-02-01

Notice of Change in Publication Schedule

In addition to the first issue that has already been published by the original publisher, there will be four more issues released this year, with scheduled publication dates in March, June, September, and December respectively.

2025-01-21

Notice: Ownership Transfer of the Journal

Starting from Volume 39 Issue 2 (2025), the ownership of Journal of Biological Regulators and Homeostatic Agents (ISSN: 0393-974X (P); 1724-6083 (O)) will be transferred from Biolife Sas to Asia Pacific Academy of Science Pte. Ltd. As of 21 January 2025, authors should make submissions to the new journal system and follow the author guidelines. Asia Pacific Academy of Science Pte. Ltd. will take over the publication of manuscripts being processed.

More Announcements...